Excessive Daytime Sleepiness

  • Yun Shen
  • Chun-Feng LiuEmail author


Excessive daytime sleepiness (EDS), one of the most common sleep abnormalities, is associated with many motor and non-motor symptoms in patients with Parkinson’s disease (PD). Its causes are multifactorial, and it is first necessary to identify and treat any possible factors causing EDS. Recent studies show that some non-pharmacologic (i.e., cognitive behavioral therapy, light therapy, repetitive transcranial magnetic stimulation) and pharmacologic (i.e., modafinil, methylphenidate, caffeine, istradefylline, sodium oxybate, atomoxetine) treatments may be effective in treating EDS in PD. Further investigations are required to determine the safety and efficacy of potential therapies and to develop novel treatment approaches for EDS in PD.


Parkinson’s disease Excessive daytime sleepiness Sleep disorders 


  1. 1.
    International Classification of Sleep Disorders III. American Academy of sleep medicine. Darien: IL; 2014.Google Scholar
  2. 2.
    Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian movement disorders group. JAMA. 2002;287(4):455–63. Scholar
  3. 3.
    Falup-Pecurariu C, Diaconu S. Sleep dysfunction in Parkinson’s Disease. Int Rev Neurobiol. 2017;133:719–42. Scholar
  4. 4.
    Loddo G, Calandra-Buonaura G, Sambati L, Giannini G, Cecere A, Cortelli P, et al. The treatment of sleep disorders in Parkinson’s disease: from research to clinical practice. Front Neurol. 2017;8:42. Scholar
  5. 5.
    Stavitsky K, Saurman JL, McNamara P, Cronin-Golomb A. Sleep in Parkinson’s disease: a comparison of actigraphy and subjective measures. Parkinsonism Relat Disord. 2010;16(4):280–3. Scholar
  6. 6.
    Chahine LM, Amara AW, Videnovic A. A systematic review of the literature on disorders of sleep and wakefulness in Parkinson’s disease from 2005 to 2015. Sleep Med Rev. 2017;35:33–50. Scholar
  7. 7.
    Ghorayeb I, Loundou A, Auquier P, Dauvilliers Y, Bioulac B, Tison F. A nationwide survey of excessive daytime sleepiness in Parkinson’s disease in France. Mov Disord. 2007;22(11):1567–72. Scholar
  8. 8.
    Montastruc JL, Brefel-Courbon C, Senard JM, Bagheri H, Ferreira J, Rascol O, et al. Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study. Clin Neuropharmacol. 2001;24(3):181–3. Scholar
  9. 9.
    Bliwise DL, Trotti LM, Juncos JJ, Factor SA, Freeman A, Rye DB. Daytime REM sleep in Parkinson’s disease. Parkinsonism Relat Disord. 2013;19(1):101–3. Scholar
  10. 10.
    Sobreira-Neto MA, Pena-Pereira MA, Sobreira EST, Chagas MHN, Fernandes RMF, Tumas V, et al. High frequency of sleep disorders in Parkinson’s disease and its relationship with quality of life. Eur Neurol. 2017;78(5–6):330–7. Scholar
  11. 11.
    Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology. 2006;67(5):853–8. Scholar
  12. 12.
    Zhu K, van Hilten JJ, Marinus J. Course and risk factors for excessive daytime sleepiness in Parkinson’s disease. Parkinsonism Relat Disord. 2016;24:34–40. Scholar
  13. 13.
    Tholfsen LK, Larsen JP, Schulz J, Tysnes OB, Gjerstad MD. Development of excessive daytime sleepiness in early Parkinson disease. Neurology. 2015;85(2):162–8. Scholar
  14. 14.
    Amara AW, Chahine LM, Caspell-Garcia C, Long JD, Coffey C, Hogl B, et al. Longitudinal assessment of excessive daytime sleepiness in early Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2017;88(8):653–62. Scholar
  15. 15.
    Wen MC, Chan LL, Tan LCS, Tan EK. Mood and neural correlates of excessive daytime sleepiness in Parkinson’s disease. Acta Neurol Scand. 2017;136(2):84–96. Scholar
  16. 16.
    Abbott RD, Ross GW, White LR, Tanner CM, Masaki KH, Nelson JS, et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology. 2005;65(9):1442–6. Scholar
  17. 17.
    Arnulf I, Neutel D, Herlin B, Golmard JL, Leu-Semenescu S, Cochen de Cock V, et al. Sleepiness in idiopathic REM sleep behavior disorder and Parkinson Disease. Sleep. 2015;38(10):1529–35. Scholar
  18. 18.
    Zhou J, Zhang J, Lam SP, Chan JW, Mok V, Chan A, et al. Excessive daytime sleepiness predicts neurodegeneration in idiopathic REM sleep behavior disorder. Sleep. 2017;40(5):zsx041. Scholar
  19. 19.
    Postuma RB, Gagnon JF, Pelletier A, Montplaisir JY. Insomnia and somnolence in idiopathic RBD: a prospective cohort study. NPJ Parkinsons Dis. 2017;3:9. Scholar
  20. 20.
    Jaussent I, Bouyer J, Ancelin ML, Berr C, Foubert-Samier A, Ritchie K, et al. Excessive sleepiness is predictive of cognitive decline in the elderly. Sleep. 2012;35(9):1201–7. Scholar
  21. 21.
    Sulzer D, Surmeier DJ. Neuronal vulnerability, pathogenesis, and Parkinson’s disease. Mov Disord. 2013;28(6):715–24. Scholar
  22. 22.
    Parkinson SG. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group JAMA. 2000;284(15):1931–8. Scholar
  23. 23.
    Tanner CM. Dopamine agonists in early therapy for Parkinson disease: promise and problems. JAMA. 2000;284(15):1971–3. Scholar
  24. 24.
    Comella CL. Daytime sleepiness, agonist therapy, and driving in Parkinson disease. JAMA. 2002;287(4):509–11. Scholar
  25. 25.
    Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson’s disease. Neurology. 2001;57(8):1392–6. Scholar
  26. 26.
    Avorn J, Schneeweiss S, Sudarsky LR, Benner J, Kiyota Y, Levin R, et al. Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch Neurol. 2005;62(8):1242–8. Scholar
  27. 27.
    O’Suilleabhain PE, Dewey RB Jr. Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease. Arch Neurol. 2002;59(6):986–9. Scholar
  28. 28.
    Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson’s disease. Mov Disord. 2003;18(6):659–67. Scholar
  29. 29.
    Arnulf I, Konofal E, Merino-Andreu M, Houeto JL, Mesnage V, Welter ML, et al. Parkinson’s disease and sleepiness: an integral part of PD. Neurology. 2002;58(7):1019–24. Scholar
  30. 30.
    Hauser RA, Gauger L, Anderson WM, Zesiewicz TA. Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord. 2000;15(4):658–63.;2-N.CrossRefPubMedGoogle Scholar
  31. 31.
    Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52(9):1908–10. Scholar
  32. 32.
    Shpirer I, Miniovitz A, Klein C, Goldstein R, Prokhorov T, Theitler J, et al. Excessive daytime sleepiness in patients with Parkinson’s disease: a polysomnography study. Mov Disord. 2006;21(9):1432–8. Scholar
  33. 33.
    Bhat S, Chokroverty S. Hypersomnia in neurodegenerative diseases. Sleep Med Clin. 2017;12(3):443–60. Scholar
  34. 34.
    Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson’s disease. Clin Neuropharmacol. 1988;11(6):512–9.CrossRefGoogle Scholar
  35. 35.
    Ferreira JJ, Desboeuf K, Galitzky M, Thalamas C, Brefel-Courbon C, Fabre N, et al. Sleep disruption, daytime somnolence and ‘sleep attacks’ in Parkinson’s disease: a clinical survey in PD patients and age-matched healthy volunteers. Eur J Neurol. 2006;13(3):209–14. Scholar
  36. 36.
    Simuni T, Caspell-Garcia C, Coffey C, Chahine LM, Lasch S, Oertel WH, et al. Correlates of excessive daytime sleepiness in de novo Parkinson’s disease: a case control study. Mov Disord. 2015;30(10):1371–81. Scholar
  37. 37.
    Rolinski M, Szewczyk-Krolikowski K, Tomlinson PR, Nithi K, Talbot K, Ben-Shlomo Y, et al. REM sleep behaviour disorder is associated with worse quality of life and other non-motor features in early Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2014;85(5):560–6. Scholar
  38. 38.
    Moreno-Lopez C, Santamaria J, Salamero M, Del Sorbo F, Albanese A, Pellecchia MT, et al. Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). Arch Neurol. 2011;68(2):223–30. Scholar
  39. 39.
    Yeh NC, Tien KJ, Yang CM, Wang JJ, Weng SF. Increased risk of Parkinson’s disease in patients with obstructive sleep apnea: a population-based, propensity score-matched, longitudinal follow-up study. Medicine (Baltimore). 2016;95(2):e2293. Scholar
  40. 40.
    Cochen De Cock V, Abouda M, Leu S, Oudiette D, Roze E, Vidailhet M, et al. Is obstructive sleep apnea a problem in Parkinson’s disease? Sleep Med. 2010;11(3):247–52. Scholar
  41. 41.
    Waters F, Faulkner D, Naik N, Rock D. Effects of polypharmacy on sleep in psychiatric inpatients. Schizophr Res. 2012;139(1–3):225–8. Scholar
  42. 42.
    Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss in Parkinson’s disease. Brain. 2007;130(Pt 6):1586–95. Scholar
  43. 43.
    Videnovic A, Noble C, Reid KJ, Peng J, Turek FW, Marconi A, et al. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol. 2014;71(4):463–9. Scholar
  44. 44.
    Valko PO, Waldvogel D, Weller M, Bassetti CL, Held U, Baumann CR. Fatigue and excessive daytime sleepiness in idiopathic Parkinson’s disease differently correlate with motor symptoms, depression and dopaminergic treatment. Eur J Neurol. 2010;17(12):1428–36. Scholar
  45. 45.
    Monderer R, Ahmed IM, Thorpy M. Evaluation of the sleepy patient: differential diagnosis. Sleep Med Clin. 2017;12(3):301–12. Scholar
  46. 46.
    Murray BJ. Subjective and objective assessment of Hypersomnolence. Sleep Med Clin. 2017;12(3):313–22. Scholar
  47. 47.
    Cochen De Cock V, Bayard S, Jaussent I, Charif M, Grini M, Langenier MC, et al. Daytime sleepiness in Parkinson’s disease: a reappraisal. PLoS One. 2014;9(9):e107278. Scholar
  48. 48.
    Takenoshita S, Nishino S. Pharmacologic management of excessive daytime sleepiness. Sleep Med Clin. 2017;12(3):461–78. Scholar
  49. 49.
    Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(Suppl 3):S2–41. Scholar
  50. 50.
    Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol. 2013;20(1):5–15. Scholar
  51. 51.
    Diederich NJ, McIntyre DJ. Sleep disorders in Parkinson’s disease: many causes, few therapeutic options. J Neurol Sci. 2012;314(1–2):12–9. Scholar
  52. 52.
    Stevens S, Cormella CL, Stepanski EJ. Daytime sleepiness and alertness in patients with Parkinson disease. Sleep. 2004;27(5):967–72. Scholar
  53. 53.
    Razmy A, Lang AE, Shapiro CM. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol. 2004;61(1):97–102. Scholar
  54. 54.
    Amara AW, Chahine LM, Videnovic A. Treatment of sleep dysfunction in Parkinson’s disease. Curr Treat Options Neurol. 2017;19(7):26. Scholar
  55. 55.
    Neikrug AB, Liu L, Avanzino JA, Maglione JE, Natarajan L, Bradley L, et al. Continuous positive airway pressure improves sleep and daytime sleepiness in patients with Parkinson disease and sleep apnea. Sleep. 2014;37(1):177–85. Scholar
  56. 56.
    Rios Romenets S, Creti L, Fichten C, Bailes S, Libman E, Pelletier A, et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease—a randomized study. Parkinsonism Relat Disord. 2013;19(7):670–5. Scholar
  57. 57.
    Leroi I, Baker P, Kehoe P, Daniel E, Byrne EJ. A pilot randomized controlled trial of sleep therapy in Parkinson’s disease: effect on patients and caregivers. Int J Geriatr Psychiatry. 2010;25(10):1073–9. Scholar
  58. 58.
    Videnovic A, Klerman EB, Wang W, Marconi A, Kuhta T, Zee PC. Timed light therapy for sleep and daytime sleepiness associated with Parkinson disease: a randomized clinical trial. JAMA Neurol. 2017;74(4):411–8. Scholar
  59. 59.
    Li Z, Tian T. Light therapy promoting dopamine release by stimulating retina in Parkinson Disease. JAMA Neurol. 2017;74(10):1267–8. Scholar
  60. 60.
    Medeiros LF, de Souza IC, Vidor LP, de Souza A, Deitos A, Volz MS, et al. Neurobiological effects of transcranial direct current stimulation: a review. Front Psych. 2012;3:110. Scholar
  61. 61.
    Civardi C, Collini A, Monaco F, Cantello R. Applications of transcranial magnetic stimulation in sleep medicine. Sleep Med Rev. 2009;13(1):35–46. Scholar
  62. 62.
    Nardone R, Holler Y, Brigo F, Tezzon F, Golaszewski S, Trinka E. Transcranial magnetic stimulation and sleep disorders: pathophysiologic insights. Sleep Med. 2013;14(11):1047–58. Scholar
  63. 63.
    Goodwill AM, Lum JAG, Hendy AM, Muthalib M, Johnson L, Albein-Urios N, et al. Using non-invasive transcranial stimulation to improve motor and cognitive function in Parkinson’s disease: a systematic review and meta-analysis. Sci Rep. 2017;7(1):14840. Scholar
  64. 64.
    Lai JB, Han MM, Xu Y, Hu SH. Effective treatment of narcolepsy-like symptoms with high-frequency repetitive transcranial magnetic stimulation: a case report. Medicine (Baltimore). 2017;96(46):e8645. Scholar
  65. 65.
    National Collaborating Centre for Chronic Conditions. Parkinson’s disease: National clinical guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians; 2006.Google Scholar
  66. 66.
    Zesiewicz TA, Sullivan KL, Arnulf I, Chaudhuri KR, Morgan JC, Gronseth GS, et al. Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the quality standards Subcommittee of the American Academy of Neurology. Neurology. 2010;74(11):924–31. Scholar
  67. 67.
    Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(Suppl 3):S42–80. Scholar
  68. 68.
    Rodrigues TM, Castro Caldas A, Ferreira JJ. Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson’s disease: systematic review and meta-analysis. Parkinsonism Relat Disord. 2016;27:25–34. Scholar
  69. 69.
    Hogl B, Saletu M, Brandauer E, Glatzl S, Frauscher B, Seppi K, et al. Modafinil for the treatment of daytime sleepiness in Parkinson’s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. 2002;25(8):905–9.CrossRefGoogle Scholar
  70. 70.
    Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005;76(12):1636–9. Scholar
  71. 71.
    Roth T, Schwartz JR, Hirshkowitz M, Erman MK, Dayno JM, Arora S. Evaluation of the safety of modafinil for treatment of excessive sleepiness. J Clin Sleep Med. 2007;3(6):595–602.CrossRefGoogle Scholar
  72. 72.
    Dolder CR, Davis LN, McKinsey J. Use of psychostimulants in patients with dementia. Ann Pharmacother. 2010;44(10):1624–32. Scholar
  73. 73.
    Devos D, Krystkowiak P, Clement F, Dujardin K, Cottencin O, Waucquier N, et al. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78(5):470–5. Scholar
  74. 74.
    Leonard BE, McCartan D, White J, King DJ. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol. 2004;19(3):151–80. Scholar
  75. 75.
    Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol. 2012;72(6):893–901. Scholar
  76. 76.
    Postuma RB, Lang AE, Munhoz RP, Charland K, Pelletier A, Moscovich M, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology. 2012;79(7):651–8. Scholar
  77. 77.
    Postuma RB, Anang J, Pelletier A, Joseph L, Moscovich M, Grimes D, et al. Caffeine as symptomatic treatment for Parkinson disease (cafe-PD): a randomized trial. Neurology. 2017;89(17):1795–803. Scholar
  78. 78.
    Ondo WG, Perkins T, Swick T, Hull KL Jr, Jimenez JE, Garris TS, et al. Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study. Arch Neurol. 2008;65(10):1337–40. Scholar
  79. 79.
    Buchele F, Hackius M, Schreglmann SR, Omlor W, Werth E, Maric A, et al. Sodium oxybate for excessive daytime sleepiness and sleep disturbance in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2018;75(1):114–8. Scholar
  80. 80.
    Wang YG, Swick TJ, Carter LP, Thorpy MJ, Benowitz NL. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. J Clin Sleep Med. 2009;5(4):365–71.CrossRefGoogle Scholar
  81. 81.
    Suzuki K, Miyamoto M, Miyamoto T, Uchiyama T, Watanabe Y, Suzuki S, et al. Istradefylline improves daytime sleepiness in patients with Parkinson’s disease: an open-label, 3-month study. J Neurol Sci. 2017;380:230–3. Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  1. 1.Department of NeurologyThe Second Affiliated Hospital of Soochow UniversitySuzhouChina

Personalised recommendations